Top

Published in:

01-12-2010 | Research Paper

Mesenchymal mode of migration participates in pulmonary metastasis of mouse osteosarcoma LM8

Authors: Yoshihiro Yui, Kazuyuki Itoh, Kiyoko Yoshioka, Norifumi Naka, Motonobu Watanabe, Yoshimi Hiraumi, Hiroshi Matsubara, Ken-ichiro Watanabe, Kazumi Sano, Tatsutoshi Nakahata, Souichi Adachi

Published in: Clinical & Experimental Metastasis | Issue 8/2010

Abstract

The outcomes of osteosarcoma patients still remain poor because of intractable pulmonary metastasis. We previously established a highly metastatic osteosarcoma cell line, LM8 from Dunn mouse osteosarcoma by in vivo selection. We herein aimed to clarify the characteristic biological features related with high metastatic potential and new target molecules to suppress pulmonary metastasis of osteosarcoma, using this syngeneic spontaneous metastatic model. LM8 cells acquired fibroblastic morphology with striking filopodia on the cell surface. Immunostaining showed faint stress fiber formation and peripherally localized integrin β1, and biochemical analyses showed the activated Cdc42 and autophosphorylation of focal adhesion kinase (FAK) in LM8 cells when compared to Dunn cells. LM8 cells had activated motility in single cell migration mode. LM8 migration was increased by a Rho-associated kinase (ROCK) inhibitor, Y-27632, while decreased by Cdc42 silencing using RNA interference system. We found that a clinically approved camptothecin analog, irinotecan suppressed the migration, Cdc42 activity, and autophosphorylation of FAK, and attenuated integrin β1 distribution selectively in LM8 cells. Daily oral administration of irinotecan significantly reduced the rate and size of pulmonary metastasis in syngeneic C3H mice. The fibroblastic morphology and activated cell migration with the dependency on Cdc42 but not Rho-ROCK signaling pathway argued that LM8 moved in mesenchymal mode of cell migration. This activated mesenchymal migration was a key component of the pulmonary metastasis of LM8 cells. The inhibition of mesenchymal migration by irinotecan, in addition to its cytotoxic effects, might be effective in preventing pulmonary metastasis of osteosarcoma.

Available only for authorised users

Lewis IJ, Nooij MA, Whelan J et al (2007) Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma Intergroup. J Natl Cancer Inst 99(2):112–128CrossRefPubMed

Meyers PA, Schwartz CL, Krailo M et al (2005) Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol 23(9):2004–2011CrossRefPubMed

Goorin AM, Schwartzentruber DJ, Devidas M et al (2003) Presurgical chemotherapy compared with immediate surgery and adjuvant chemotherapy for nonmetastatic osteosarcoma: Pediatric Oncology Group Study POG-8651. J Clin Oncol 21(8):1574–1580CrossRefPubMed

Kager L, Zoubek A, Potschger U et al (2003) Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. J Clin Oncol 21(10):2011–2018CrossRefPubMed

Dunn TB, Andervont HB (1963) Histology of some neoplasms and non-neoplastic lesions found in wild mice maintained under laboratory conditions. J Natl Cancer Inst 31:873–901PubMed

Asai T, Ueda T, Itoh K et al (1998) Establishment and characterization of a murine osteosarcoma cell line (LM8) with high metastatic potential to the lung. Int J Cancer 76(3):418–422CrossRefPubMed

Sahai E (2007) Illuminating the metastatic process. Nat Rev Cancer 7(10):737–749CrossRefPubMed

Gupta GP, Massague J (2006) Cancer metastasis: building a framework. Cell 127(4):679–695CrossRefPubMed

Pantel K, Brakenhoff RH (2004) Dissecting the metastatic cascade. Nat Rev Cancer 4(6):448–456CrossRefPubMed

10.

Yamaguchi H, Wyckoff J, Condeelis J (2005) Cell migration in tumors. Curr Opin Cell Biol 17(5):559–564CrossRefPubMed

11.

Friedl P, Wolf K (2003) Tumour-cell invasion and migration: diversity and escape mechanisms. Nat Rev Cancer 3(5):362–374CrossRefPubMed

12.

Friedl P (2004) Prespecification and plasticity: shifting mechanisms of cell migration. Curr Opin Cell Biol 16(1):14–23CrossRefPubMed

13.

Thiery JP (2002) Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2(6):442–454CrossRefPubMed

14.

Poste G, Fidler IJ (1980) The pathogenesis of cancer metastasis. Nature 283(5743):139–146CrossRefPubMed

15.

Ren XD, Kiosses WB, Schwartz MA (1999) Regulation of the small GTP-binding protein Rho by cell adhesion and the cytoskeleton. EMBO J 18(3):578–585CrossRefPubMed

16.

Mettouchi A, Klein S, Guo W et al (2001) Integrin-specific activation of Rac controls progression through the G(1) phase of the cell cycle. Mol Cell 8(1):115–127CrossRefPubMed

17.

Yoshioka K, Nakamori S, Itoh K (1999) Overexpression of small GTP-binding protein RhoA promotes invasion of tumor cells. Cancer Res 59(8):2004–2010PubMed

18.

Sotobori T, Ueda T, Myoui A et al (2006) Bone morphogenetic protein-2 promotes the haptotactic migration of murine osteoblastic and osteosarcoma cells by enhancing incorporation of integrin beta1 into lipid rafts. Exp Cell Res 312(19):3927–3938CrossRefPubMed

19.

Nitta N, Tsuchiya T, Yamauchi A et al (2007) Quantitative analysis of eosinophil chemotaxis tracked using a novel optical device—TAXIScan. J Immunol Methods 320(1–2):155–163CrossRefPubMed

20.

Sano K, Yoshikawa M, Hayasaka S et al (2003) Simple non-ion-paired high-performance liquid chromatographic method for simultaneous quantitation of carboxylate and lactone forms of 14 new camptothecin derivatives. J Chromatogr B Analyt Technol Biomed Life Sci 795(1):25–34CrossRefPubMed

21.

Itoh K, Yoshioka K, Akedo H et al (1999) An essential part for Rho-associated kinase in the transcellular invasion of tumor cells. Nat Med 5(2):221–225CrossRefPubMed

22.

Furman WL, Crews KR, Billups C et al (2006) Cefixime allows greater dose escalation of oral irinotecan: a phase I study in pediatric patients with refractory solid tumors. J Clin Oncol 24(4):563–570CrossRefPubMed

23.

Kuppens IE, Dansin E, Boot H et al (2006) Dose-finding phase I clinical and pharmacokinetic study of orally administered irinotecan in patients with advanced solid tumors. Clin Cancer Res 12(12):3774–3781CrossRefPubMed

24.

Drengler RL, Kuhn JG, Schaaf LJ et al (1999) Phase I and pharmacokinetic trial of oral irinotecan administered daily for 5 days every 3 weeks in patients with solid tumors. J Clin Oncol 17(2):685–696PubMed

25.

Wang W, Goswami S, Sahai E et al (2005) Tumor cells caught in the act of invading: their strategy for enhanced cell motility. Trends Cell Biol 15(3):138–145CrossRefPubMed

26.

Wyckoff JB, Pinner SE, Gschmeissner S et al (2006) ROCK- and myosin-dependent matrix deformation enables protease-independent tumor-cell invasion in vivo. Curr Biol 16(15):1515–1523CrossRefPubMed

27.

Philippar U, Roussos ET, Oser M et al (2008) A Mena invasion isoform potentiates EGF-induced carcinoma cell invasion and metastasis. Dev Cell 15(6):813–828CrossRefPubMed

28.

Ellenbroek SI, Collard JG (2007) Rho GTPases: functions and association with cancer. Clin Exp Metastasis 24(8):657–672CrossRefPubMed

29.

Condeelis J, Segall JE (2003) Intravital imaging of cell movement in tumours. Nat Rev Cancer 3(12):921–930CrossRefPubMed

30.

Giampieri S, Manning C, Hooper S et al (2009) Localized and reversible TGFbeta signalling switches breast cancer cells from cohesive to single cell motility. Nat Cell Biol 11(11):1287–1296CrossRefPubMed

31.

Vicente-Manzanares M, Cabrero JR, Rey M et al (2002) A role for the Rho-p160 Rho coiled-coil kinase axis in the chemokine stromal cell-derived factor-1alpha-induced lymphocyte actomyosin and microtubular organization and chemotaxis. J Immunol 168(1):400–410PubMed

32.

Vega FM, Ridley AJ (2008) Rho GTPases in cancer cell biology. FEBS Lett 582(14):2093–2101CrossRefPubMed

33.

Nobes CD, Hall A (1999) Rho GTPases control polarity, protrusion, and adhesion during cell movement. J Cell Biol 144(6):1235–1244CrossRefPubMed

34.

Wilkinson S, Paterson HF, Marshall CJ (2005) Cdc42-MRCK and Rho-ROCK signalling cooperate in myosin phosphorylation and cell invasion. Nat Cell Biol 7(3):255–261CrossRefPubMed

35.

Yoshikawa H, Yoshioka K, Nakase T et al (2009) Stimulation of ectopic bone formation in response to BMP-2 by Rho kinase inhibitor: a pilot study. Clin Orthop Relat Res 467(12):3087–3095CrossRefPubMed

36.

Kashima T, Nakamura K, Kawaguchi J et al (2003) Overexpression of cadherins suppresses pulmonary metastasis of osteosarcoma in vivo. Int J Cancer 104(2):147–154CrossRefPubMed

37.

Pommier Y, Redon C, Rao VA et al (2003) Repair of and checkpoint response to topoisomerase I-mediated DNA damage. Mutat Res 532(1–2):173–203PubMed

38.

Pommier Y, Cherfils J (2005) Interfacial inhibition of macromolecular interactions: nature’s paradigm for drug discovery. Trends Pharmacol Sci 26(3):138–145CrossRefPubMed

39.

Nitiss J, Wang JC (1988) DNA topoisomerase-targeting antitumor drugs can be studied in yeast. Proc Natl Acad Sci USA 85(20):7501–7505CrossRefPubMed

Title: Mesenchymal mode of migration participates in pulmonary metastasis of mouse osteosarcoma LM8
Authors: Yoshihiro Yui
Kazuyuki Itoh
Kiyoko Yoshioka
Norifumi Naka
Motonobu Watanabe
Yoshimi Hiraumi
Hiroshi Matsubara
Ken-ichiro Watanabe
Kazumi Sano
Tatsutoshi Nakahata
Souichi Adachi
Publication date: 01-12-2010
Publisher: Springer Netherlands
Published in: Clinical & Experimental Metastasis / Issue 8/2010
Print ISSN: 0262-0898
Electronic ISSN: 1573-7276
DOI: https://doi.org/10.1007/s10585-010-9352-x

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 8/2010

KISS1 over-expression suppresses metastasis of pancreatic adenocarcinoma in a xenograft mouse model

Effects of dietary fat on spontaneous metastasis of Lewis lung carcinoma in mice

Co-expression of CD147/EMMPRIN with monocarboxylate transporters and multiple drug resistance proteins is associated with epithelial ovarian cancer progression

Actin-sequestering protein, thymosin beta-4, is a novel hypoxia responsive regulator

p-AKT overexpression in primary renal cell carcinomas and their metastases

Serum follistatin in patients with prostate cancer metastatic to the bone

Keynote webinar | Spotlight on antibody–drug conjugates in cancer